Bajaj Healthcare rose 3.07% to Rs 906.95 after the drug maker announced starting commercial production of Nimesulide API at Tarapur unit in Maharashtra.
The company has received approval from FDA Maharashtra (India), to manufacture and market Nimesulide API as approved medication for pain relief and prevention of fever in India and will commence its commercial production from tomorrow (3 September) onwards.In FY21, the company acquired stressed assets from the Saraswat Cooperative Bank under SARFAESI Act, 2002, which comprises of three manufacturing units and one engineering unit at MIDC, Tarapur. It has installed capacity of 111 MT per month.
The firm has received an approval to start its commercial production in one of the manufacturing unit at Tarapur.
Bajaj Healthcare a leading manufacturer of APIs, intermediates and formulations established in the year 1993. The company reported 25.7% rise in net profit to Rs 19.21 crore on a 32.8% increase in revenue from operations to Rs 185.68 crore in Q1 FY22 over Q1 FY21
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app